The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Large B-cell lymphoma: relapsing post-axi-cel
Sattva Neelapu, MD, Anderson Cancer Center, Houston, TX, outlines an analysis of large B-cell lymphoma patients who relapsed post-axi-cel. The loss of CD19 due to the downregulation and alternating splicing of the gene is believed to be responsible for relapse after treatment with this CAR. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
